How Much Does Dupuytren Surgery Cost?

Dupuytren surgery costs anywhere from roughly $600 to over $11,000 per procedure in direct medical charges, depending on which treatment you receive and where it is performed. That range is enormous because “Dupuytren surgery” is not a single operation. Three distinct procedures dominate treatment today, each with very different price tags, recovery timelines, and odds of recurrence. The real cost picture gets more complicated once you factor in rehab visits, time off work, and the strong likelihood you will need a second or third treatment down the road.

Three Procedures, Three Price Points

The most important thing to understand about Dupuytren treatment costs is that the procedure your surgeon recommends will be the biggest single driver of your bill. The three main options are needle aponeurotomy (sometimes called percutaneous needle fasciotomy), collagenase injection, and open fasciectomy. They differ in how aggressively they address the diseased tissue, how long recovery takes, and how much they cost upfront.

Needle aponeurotomy is the least invasive and least expensive. A surgeon uses a needle to perforate the contracted cord in the palm, then manually straightens the finger. It can be done in an office with local anesthesia, and one study found a standardized direct cost of about $624 per digit.¹ Another analysis placed the mean cost closer to $4,657, though that figure included facility and anesthesia charges that vary widely by setting.²

Collagenase injection (marketed as Xiaflex in the United States) involves injecting an enzyme into the cord that dissolves the collagen, followed by a manipulation visit a day or two later. Direct costs for collagenase have been reported at around $4,200 for the initial treatment, with much of that driven by the price of the drug itself.¹ A separate retrospective study found total episode-of-care costs of about $7,657 over three months for collagenase patients, which included follow-up visits and ancillary services.³

Open fasciectomy is the traditional surgical approach. The surgeon makes an incision in the palm and physically removes the diseased tissue. It is the most invasive option and the most expensive. Mean costs have been reported at about $5,300 in standardized direct charges and over $11,000 when operating-room and anesthesia fees are included.² Claims-database analyses show three-month total costs of roughly $8,500 for fasciectomy patients, compared to about $7,700 for collagenase patients.³

Why Cost Estimates Vary So Widely

If you have tried to research this before reading here, you probably noticed that the numbers seem to contradict each other. One study says collagenase costs about $1,400, another says close to $7,700. Those are not errors. They reflect completely different ways of counting costs, which is useful to understand before you start comparing quotes from different surgeons.

The biggest variable is what gets included in the bill. A “direct cost” figure typically counts the surgeon’s fee, supplies, and the procedure itself but not the operating room, anesthesia, or follow-up appointments. A “total episode of care” figure bundles everything for a set period afterward, including lab work, therapy visits, and sometimes imaging. One retrospective study that compared collagenase to fasciectomy found that fasciectomy patients had higher outpatient surgical-visit costs (about $3,600 versus $826) but lower drug costs, because the collagenase medication itself accounted for a large share of the injection group’s bill.³

Geography matters too. A national analysis of U.S. Dupuytren procedures found that needle fasciotomy was the cheapest option in every region, but the cost of fasciectomy and collagenase varied substantially between the Northeast, Midwest, South, and West. In some regions, collagenase ended up being the most expensive intervention rather than the mid-range one.⁴ The total number of Dupuytren procedures in the United States grew more than 300% between 2015 and 2018 across all regions, which suggests increasing demand but has not standardized pricing.⁴

How Anesthesia Choice Changes the Bill

One cost lever that patients rarely think about is anesthesia. Needle aponeurotomy and collagenase injection are typically performed with local anesthesia in an office, which keeps costs low. Open fasciectomy has traditionally involved regional anesthesia (a nerve block) or even general anesthesia in an outpatient surgical center, both of which add facility fees and anesthesiologist charges.

A growing trend is “wide-awake” surgery using local anesthetic with epinephrine (commonly called WALANT), which allows fasciectomy to be performed in an office or minor procedure room rather than a full operating suite. One study found that WALANT reduced anesthesia-related costs by about 61% compared to general or regional anesthesia, and was associated with markedly reduced total reimbursement for the procedure overall.⁵ A separate nationwide analysis found that wide-awake fasciectomy patients had fewer 30-day emergency department visits and similar complication rates compared to those under traditional anesthesia, though they had a slightly higher rate of subsequent Dupuytren interventions within two years.⁶ If your surgeon offers WALANT fasciectomy, it is worth asking about, because it can substantially reduce the facility component of your bill.

The Real Cost Problem Is Recurrence

The upfront price of a single procedure is only part of the story. Dupuytren disease tends to come back. The cord can reform, the contracture can return, and many people need a second or third treatment over the course of their lives. This is where the cheapest initial procedure does not always stay the cheapest option.

A cost-effectiveness analysis that modeled lifetime treatment found that needle aponeurotomy for every round of treatment was the least expensive strategy overall, with a mean total cost of about $3,340 for a low-severity contracture at the knuckle joint. Using open fasciectomy every time was the most expensive at about $25,400 for the same scenario, roughly eight times higher.⁷ That said, the model found that lifetime quality-adjusted outcomes were slightly better with fasciectomy, which makes sense because it tends to last longer before the contracture returns.

The five-year cumulative costs, including retreatments, help illustrate this tradeoff. One study calculated them at about $1,540 per digit for needle aponeurotomy, $5,950 for collagenase, and $5,500 for fasciectomy.¹ Notice that collagenase ended up slightly more expensive than fasciectomy at five years, despite being cheaper upfront, because it recurred more often and some of those patients ultimately needed surgery anyway.

A UK trial (the DISC trial) captured this dynamic in a different way. At one year, collagenase injection saved about £1,090 compared to limited fasciectomy with nearly equivalent outcomes. But by two years, collagenase was still cheaper yet measurably less effective, meaning the cost savings came at the price of worse hand function over time.⁸ This is the kind of tradeoff that does not show up in a simple price comparison.

What Medicare Patients Actually Pay

If you are on Medicare, the cost picture looks somewhat different from the general estimates above because Medicare reimbursement rates are standardized. A real-world Medicare claims analysis found that the total average annual healthcare costs were similar whether patients received collagenase or fasciectomy: about $7,270 for collagenase versus $6,220 for fasciectomy, a difference that was not statistically significant.⁹ The breakdown was telling, though: collagenase patients had lower outpatient facility and physician office costs but substantially higher “professional services” costs, driven entirely by the price of the drug. Fasciectomy patients had higher surgeon and facility costs but did not need to pay for the collagenase medication.

Your out-of-pocket share as a Medicare beneficiary depends on your specific plan, deductible status, and whether you have supplemental coverage. But the overall spending pattern suggests that from Medicare’s perspective, the two approaches end up costing roughly the same in the first year. The real difference emerges later, when recurrence rates diverge.

Lost Wages and Time Off Work

The sticker price of the procedure is not the only financial hit. If you work with your hands or need both hands for your job, the recovery period matters. Fasciectomy typically requires more time off than needle aponeurotomy or collagenase injection, and the data backs up that intuition with real numbers.

Commercially insured patients treated with collagenase were significantly less likely to use short-term disability leave compared to fasciectomy patients (about 10% versus 20%), and their average disability costs in the year following treatment were roughly $375 versus $1,108.¹⁰ In a European study, lost productivity per patient was estimated at about €2,600, calculated using the “human capital method” that assigns a monetary value to the wages a worker misses during recovery.¹¹

A broader look at the economic burden confirms the pattern. Workers with Dupuytren contracture averaged about 14 days of work loss per year compared to 7 days for matched controls, and their total annual costs (medical plus lost productivity) ran roughly $8,700 versus $4,500.¹² That gap includes higher rates of physical therapy visits and prescription use, not just the surgery itself. If you are weighing a less invasive procedure with higher recurrence against a more invasive one with longer recovery, the lost-wage calculation could tip the balance depending on your occupation.

Is the Cheapest Option the Best Value?

Health economists have tried to answer this question using cost-effectiveness models, and the answer is less obvious than you might expect. Needle aponeurotomy is consistently the cheapest option by a wide margin, but economic models that weigh both cost and quality of life over a full lifetime still find reasonable arguments for more expensive approaches.

A UK health technology assessment found that limited fasciectomy generated the greatest quality-of-life gains, and its incremental cost over needle fasciotomy was roughly £1,200 for an additional 0.11 quality-adjusted life-years. The resulting cost per quality-adjusted life-year was about £10,900, which falls well within thresholds that most health systems consider acceptable.¹³ In that same analysis, collagenase came out worse than both alternatives on a cost-per-QALY basis, generating fewer quality-of-life gains than fasciectomy while costing more than needle fasciotomy.

A U.S. cost-effectiveness study reached a similar conclusion from a different angle. It found that fasciectomy cost over $820,000 per quality-adjusted life-year gained versus no treatment, a staggeringly high number that reflects how modest the quality-of-life impact of hand contracture treatment is in absolute terms. Needle aponeurotomy was far more efficient at about $96,500 per QALY. Collagenase fell somewhere in between, but its cost-effectiveness was extremely sensitive to the drug’s price: at $250 per injection series it was competitive, at the U.S. market price of $5,400 per injection it was not.¹⁴

The practical takeaway: if you are paying a significant share of the cost yourself, needle aponeurotomy gives you the most contracture relief per dollar spent. If your insurance covers most of the bill and your contracture is severe, fasciectomy may be worth the longer recovery because it lasts longer. Collagenase sits in an awkward middle in terms of value, competitive on recovery time but undermined by the medication’s high price.

How Costs Differ Outside the United States

Most of the dollar figures above come from the U.S. healthcare system, where prices are generally higher than anywhere else. A Swedish retrospective study found that collagenase injection cost about $1,418 and fasciectomy about $2,103, roughly a third less for the injection and with equivalent short-term outcomes.¹⁵ Those figures are dramatically lower than U.S. equivalents, partly because facility fees, surgeon fees, and drug prices are all lower in systems with negotiated pricing.

Practice patterns also vary in ways that affect the bill. A European survey found that the share of patients treated as inpatients ranged from about 9% in Nordic countries to 80% in Eastern Europe, a gap that translates into vastly different hospital charges.¹⁶ Most procedures across Europe were performed in public hospitals and covered by public insurance, meaning the out-of-pocket burden for patients was low regardless of total system cost. If you are seeking treatment abroad or comparing systems, the combination of lower unit prices and public coverage makes Dupuytren treatment far less financially burdensome in most other high-income countries.

What Xiaflex’s Availability Means for Your Options

Collagenase injection (Xiaflex) has had a complicated commercial history. It was withdrawn from the European market in 2020 due to a commercial dispute, not a safety issue, and its availability in other markets has fluctuated. In the United States it remains available, but its high list price has made it a contentious choice. As the cost-effectiveness studies above show, collagenase only looks like a good deal if the drug price comes down or if you heavily weight the shorter recovery and lower disability costs against the higher medication charges.

If Xiaflex is not available to you or your insurer refuses to cover it, the remaining options are needle aponeurotomy and open fasciectomy. The good news is that needle aponeurotomy, the cheapest option by every measure, also has the fastest recovery. Its weakness is a higher recurrence rate, but since the procedure is quick and inexpensive to repeat, that tradeoff is often acceptable, particularly for older patients or those with mild to moderate contractures. Fasciectomy remains the gold standard for severe or multi-digit disease, especially in younger patients with aggressive disease who would otherwise face many rounds of less durable treatments.

Severity and Joint Location Affect Total Spending

Not all Dupuytren contractures are equal, and the same procedure costs more when the disease is more severe or involves harder-to-treat joints. The cost-effectiveness model that tracked lifetime treatment found that costs varied by both the severity of the contracture and whether it affected the knuckle joint or the middle joint of the finger. For a low-severity knuckle contracture treated with needle aponeurotomy each time, the mean lifetime cost was about $3,340. For the same strategy applied to a more severe contracture or one at the middle finger joint, costs were higher because those scenarios tend to recur more aggressively and need more treatments.⁷

This is worth discussing with your surgeon before choosing a procedure. A mild contracture at the knuckle joint is the ideal candidate for needle aponeurotomy because outcomes are good and recurrence, when it happens, is manageable. A severe contracture at the middle finger joint may justify the higher upfront cost and longer recovery of fasciectomy because the alternative is a series of repeated, less durable treatments that add up over time. The individual clinical picture, not just the procedure’s sticker price, should drive the decision.